An argument for maintenance of sinus rhythm in patients with atrial fibrillation

Circulation

Volumn 111, Issue 23, 2005, Pages 3150-3157

  Zimetbaum, Peter ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; DOFETILIDE; PROPAFENONE; SOTALOL;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HEART PROARRHYTHMIA; HEART RATE; HEART VENTRICLE ARRHYTHMIA; HUMAN; MORTALITY; NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; SINUS RHYTHM; SURGICAL TECHNIQUE;

EID: 20544435230     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.104.537175     Document Type: Note

References (48)

1. Wyse DG, Waldo AL, Domanski MJ, Rosenberg Y, Schron E, Kellen J, Greene H, Mickel M, Dalquist J, Corley S. Comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825-1833.
2. Van Gelder I, Hagens V, Bosker H, Kingma J, Kamp O, Kingma T, Said S, Darmanata J, Timmermans A, Tijssen J, Crijns J. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834-1840.
3. Carlsson J, Miketic S, Windeler J, Cuneo A, Haun S, Micus S, Walter S, Tebbe U. Randomized trial of rate-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol. 2003;41:1690-1696.
4. Hohnloser S, Kuick Karl, Lilienthal J. Rhythm or rate control in atrial fibrillation: Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomized trial. Lancet. 2000;356:1789-1794.
5. Steinberg J, Sadaniantz A, Kron J, Krahn A, Denny D, Daubert J, Campbell B, Havranek E, Murray K, Olshansky B, O'Neill G, Sami M, Schmidt S, Storm R, Zabalgoitia M, Miller J, Chandler M, Nasco E, Greene L. Analysis of cause specific mortality in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study. Circulation. 2004;109:1973-1980.
6. The AFFIRM Investigators. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation. 3004;109: 1509-1513.
7. Villareal R, Hariharan R, Liu B, Kar B, Lee V, Elayda M, Lopez J, Rasekh A, Wilson J, Massumi A. Postoperative atrial fibrillation and mortality after coronary artery bypass surgery. J Am Coll Cardiol. 2004; 43:742-748.
8. Crenshaw B, Ward S, Granger C, Stebbins A, Topol E, Califf R. Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience: Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol. 1997;30:406-413.
9. Wong C, White H, Wilcox R, Criger D, Califf R, Topol E, Ohman E. New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience. Am Heart J. 2000;140:878-885.
10. Wolf PA, Mitchell JB, Baker CS, Kannel WB, D'Agostino RB. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med. 1998;158:229-234.
11. Dries D, Exner D, Gersh B, Domanski M, Waclawiw M, Stevenson L. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. J Am Coll Cardiol. 1998;32:695-703.
12. Olivotto I, Cecchi F, Casey S, Dolara A, Traverse J, Maron B. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation. 2001;104:2517-2524.
13. Glotzer T, Hellkamp M, Zimmerman J, Sweeney M, Yee R, Marinchak R, Cook J, Paraschos A, Love J, Radoslovich F, Lee K, Lamas G. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke. Circulation. 2003;107:1614-1619.
14. Benjamin E, Wolf P, D'Agostino R. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98: 946-952.
15. Atrial fibrillation as a contributing cause of death and Medicare hospitalization: United States, 1999. MMWR Morb Mortal Wkly Rep. 2003;52: 128-131.
16. Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, Kus T, Lambert J, Dubuc M, Gagne P, Nattel S, Thibault B, for the Canadian Trial of Atrial Fibrillation Investigators. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med. 2000;342:913-920.
17. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol 2003;42:20-29.
18. Go A, Hylek E, Phillips K, Chang Y, Henault L, Selby J, Singer D. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors In Atrial Fibrillation Study. JAMA. 2001;285:2370-2375.
19. Wolf P, Abbott R, Kannel W. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-988.
20. Essebag V, Hadjis T, Platt R, Pilote L. Amiodarone and the risk of bradyarrhythmia requiring permanent pacemaker in elderly patients with atrial fibrillation and prior myocardial infarction. J Am Coll Cardiol 2003;41:249-254.
21. Wang T, Larson M, Levy D. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation. 2003;107:2920-2925.
22. Deedwandia PC, Singh B, Ellenbogen K, Fisher S. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT). Circulation. 1998;98:2574-2579.
23. Pederson O, Bagger H., Keller N, Marchant B, Kober L, Torp Pederson C. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish Investigation of Arrhythmia and Mortality on Dofetilide (diamond) study. Circulation. 2001;104:292-296.
24. Rationale and design of a study assessing treatment strategies of atrial fibrillation in patients with heart failure: the Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial. Am Heart J. 2002;14:597-607.
25. Pappone C, Rosanio S, Augello G, Callus G, Vicedomini G, Mazzone P, Gulletta S, Gugliotta F, Pappone A, Santinelli V, Tortoriello V, Sala S, Zangrillo A. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. J Am Coll Cardiol. 2003;42:185-197.
26. Oral H, Scharf C, Chugh A, Hall B, Cheung P, Good E, Veerareddy S, Pelosi F, Morady F. Catheter ablation for paroxysmal atrial fibrillation: segmental pulmonary vein ostial ablation versus left atrial ablation. Circulation. 2003;108:2355-2360.
27. Hsu L, Jais P, Sanders P, Garrigue S, Hocini M, Sacher F, Takahashi Y, Rotter M, Pasquie J, Scavee C, Bordachar P, Clementy J, Haissaguerre M. Catheter ablation of atrial fibrillation in congestive heart failure. N Engl J Med. 2004;351:2372-2378.
28. Pappone C, Manguso F, Vicedomini G, Gugliotta F, Santinelli O, Fero A, Gulletta S, Sala S, Sora N, Paglino G, Augello G, Agricola E, Zangrillo A, Alfieri O, Santineeli V. Prevention of iatrogenic atrial tachycardia after ablation of atrial fibrillation. Circulation. 2004;110:3036-3042.
29. Stevenson W, Stevenson L. Atrial fibrillation and heart failure: five more years. N Engl J Med. 2004;351:2437-2438.
30. Saad E, Marrouche N, Saad C, Ha E, Bash D, White R, Rhodes J, Prieto L, Martin D, Saliba W, Schweikert R, Natale A. Pulmonary vein stenosis after catheter ablation of atrial fibrillation: emergence of a new clinical syndrome. Ann Intern Med. 2003;138:634-638.
31. Pappone C, Oral H, Santinelli V, Vicedomini G, Lang C, Manguso F, Torracca L, Benussi S, Alfieri O, Hong R, Lau W, Hirata K, Shikuma N, Hall B, Morady F. Atrio-esophageal fistula as a complication of percutaneous transcatheter ablation of atrial fibrillation. Circulation. 2004;109: 2724-2726.
32. Gaynor S, Diodato M, Prasad S, Ishii Y, Schuessler R, Bailey M, Damiano N, Bloch J, Moon M, Damiano R. A prospective, single-center clinical trial of a modified Cox maze procedure with bipolar radiofrequency ablation. J Thorac Cardiovasc Surg. 2004;128:535-542.
33. Coyne KS, Grandy S, Paramore C, Mercader M, Zimetbaum P. Resource use and costs associated with atrial fibrillation in the US. Circulation. 2004;110(suppl III):III-826. Abstract.
34. Marshall D, Levy A, Vidaillet H, Fenwick E, Slee A, Blackhouse G, Greene H, Wyse G, Nichol G, O'Brien B. Cost-effectiveness of rhythm versus rate control in atrial fibrillation. Ann Intern Med. 2004;141: 653-661.
35. Coyne K, Margolis M, Grandy S, Zimetbaum P. The state of patient-reported outcomes in atrial fibrillation: a review of current measures. Pharmacoeconomics. In press.
36. Hagens V, Ranchor A, Van Sonderen E, Bosker H, Kamp O, Tijssen J, Kingma JH, Crijns H, Van Gelder I. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation: results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol. 2004;43:241-247.
37. 36a. Singh B, Singh S, Reda D, Tang X, Lopez B, Harris C, Fletcher R, Sharma S, Atwood J, Jacobsen A, Lewis D, Raisch D, Ezekowitz M. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005; 352:1861-1872.
38. Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa K, Saku K. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol. 2003;41: 2197-2204.
39. Madrid A, Peng J, Zamora J, Marin I, Bernai E, Escobar C, Munos-Tinoco C, Rebollo J, Moro C. The role of angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases. Pacing Clin Electrophysiol. 2004;27:1405-1410.
40. Roden D. Antiarrhythmic drugs: past, present and future. J Cardiovasc Electrophysiol. 2004;26:57C-66C.
41. Roy D, Rowe B, Steill I, Coutu B, Ip J, Phaneuf D, Lee J, Vidaillet H, Dickinson G, Grant S, Ezrin A, Beatch G. A randomized, controlled trial of RSD 1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J Am Coll Cardiol. 2004;44:2355-2361.
42. Salenger R, Lahey S, Saltman A. The completely endoscopic treatment of atrial fibrillation: report on the first 14 cases with early results. Heart Surgery Forum. 2004;7:E554-E558.
43. Hauser T, Josephson ME, Zimetbaum P. Safety and feasibility of a clinical pathway for the outpatient initiation of antiarrhythmic medications in patients with atrial fibrillation and flutter. Am J Cardiol. 2003;91:1437-1441.
44. Kim M, Morady F, Conlon B, Kronick S, Lowell M, Bruckman D, Armstrong W, Eagle K. A prospective, randomized, controlled trial of an emergency department-based atrial fibrillation treatment strategy with low-molecular-weight heparin. Ann Emerg Med. 2002;40:187-192.
45. Zimetbaum P, Reynolds MR, Ho KK, Gaziano T, McDonald MJ, McClennen S, Berezin R, Josephson ME, Cohen DJ. Impact of a practice guideline for patients with atrial fibrillation on medical resource utilization and costs. Am J Cardiol. 2003;92:677-681.
46. Botkin SB, Dhanekula LS, Olshansky B. Outpatient cardioversion of atrial arrhythmias: efficacy, safety, and costs. Am Heart J. 2003;145: 233-238.
47. Lewis T. Auricular fibrillation. In: Clinical Disorders of the Heart Beat: A Handbook for Practitioners and Students. London, England: Shaw and Sons; 1912:71-90. Chapter 6.
48. Haissaguerre M, Shah D, Takahashi A, Hocini M, Quiniou G, Garrigue S, LeMouroux A, Le Metayer P, Clementy J. Spontaneous initiation of atrial fibrillation by ectopic beats originating in pulmonary veins. N Engl J Med. 1998;339:659-666.